-
新型HER2双表位ADC药物疗效可期丨肿瘤研究展播
研究名称：Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Hum...
热度11782026-03-11 -
早期三阴性乳腺癌治疗迈向“蒽环紫杉铂类三驾马车”新时代丨肿瘤研究展播
研究名称：Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in w...
热度13512026-03-11 -
AI全程驱动，验证SNF分型指导HR+/HER2-乳腺癌精准治疗丨肿瘤研究展播
研究名称：Precision treatment with artificial intelligence assisted subtyping enhance...
热度10562026-03-11 -
为内分泌进展后HR+/HER2-晚期乳腺癌患者提供新治疗选择丨肿瘤研究展播
研究名称：Tibremciclib or Placebo Plus Fulvestrant in Hormone Receptor-Positive and E...
热度10432026-03-11 -
新型CDK2/4/6i为HR+/HER2-提供新型治疗方案丨肿瘤研究展播
研究名称：Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previou...
热度11162026-03-11 -
见刊NEJM！T-DXd联合帕妥珠单抗相对于现行标准治疗具有显著优势丨肿瘤研究展播
研究名称：Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast ...
热度10932026-03-11 -
neoCARHP研究革新HER2阳性乳腺癌治疗理念丨肿瘤研究展播
研究名称：Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carbopla...
热度10882026-03-11 -
节拍卡培他滨联合芳香化酶抑制剂为CDK4/6抑制剂不耐受者提供新选择丨肿瘤研究展播
研究名称：Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Pati...
热度9952026-03-11 -
新型CLDN18.2 ADC治疗晚期胃癌临床I期研究结果丨肿瘤研究展播
研究名称：CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or ga...
热度8922026-03-11 -
EGFR×HER3双抗ADC实现食管鳞癌靶向治疗新突破丨肿瘤研究展播
研究名称：A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic ...
热度8942026-03-11
